PARADISE: a project for personalised relapse prediction in autoimmune disease (vasculitis)

PARADISE is an EU-funded project lead by a consortium of 8 partners, coordinated by Mark Little (ERN RITA Stream Lead for Autoinflmmatory Diseases). Patient advocates are also active among the project’s partners, including Julie Power, director of Vasculitis Ireland Awareness and patient partner for the RITA Patient Advocacy Group. Recently, they launched a basic information tool video for people living with Vasculitis, people new to these conditions – healthcare, research and academia, the public and those involved in planning services.  It has been reviewed ethically, legally, and clinically by the PARADISE consortia members. The videos are now available in 9 languages and entitled ’10 things to know about vasculitis: in English, Croatian, Dutch, French, German, Spanish, Swedish, Italian and Greek.

We invite all our network members to share this content widely among the physicians and patient communities to raise awareness of these conditions, improve access to care and generally lead to better management and quality of life.

PARADISE aims to give a practical response to the medication treating autoimmuse disorders, which often to the suppression of the immune system. They aim to “develop a personalised prediction tool that accurately defines the patient’s risk of disease recurrence so that medication doses can be tailored and, in some cases, stopped safely”. By using systemic vasculitis as a typical autoimmune disease, bringing together clinical, biomarker and smartphone derived wellbeing data to inform predictive algorithms underpinning a physician tool”.